ArticleTranslational cancer research2025
Prognosis and chemotherapy efficacy in small-tumor breast cancer with different immune subtypes: a SEER-based study.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In the case of lymph node metastasis, small-tumor breast cancer patients show distinct survival rates. Current studies have not conducted in-depth analyses of small-tumor patients with different immune subtypes and different lymph node metastases. This study aimed to examine the survival outcomes and chemotherapy efficacy of patients with different immune subtypes. Methods: Retrospective clinical data of small-tumor breast cancer patients were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. A multivariate Cox proportional hazards model was used to analyze prognostic factors. Survival analysis was stratified based on stage T, stage N and immune subtypes. Results: Patients with T1cN2+ stage had the highest risk of death. However, in T1N1 stage cancers, compared with patients of other subtypes in T1mi/a-bN1 stage, the overall survival (OS) and breast cancer-specific survival (BCSS) of patients with T1mi/a-bN1 hormone receptor negative human epidermal growth factor receptor 2 positive (HR-HER2+) were significantly worse. HR+HER2- subtype patients showed a similar trend. Additionally, postoperative adjuvant chemotherapy (AC) was a favorable prognostic factor for OS in small-tumor breast cancer patients [hazard ratio (HR) =0.78, P<0.001] but had no significant effect on BCSS (HR =1.1, P=0.11). In the pT1mi/a-bN0-1 HR+HER2- subtype and pT1mi/a-bN0 HR-HER2-/HR+HER2+ subtype patients, AC did not significantly improve survival (P>0.05). Conclusions: In addition to T1cN2+ stage or HR-HER2- subtype, this study identified T1mi/a-bN1 HR-HER2+ subgroup as a high-risk type in small-tumor breast cancer. And small-tumor breast cancer patients do not usually benefit from AC. AC may not be recommended for certain subgroups, such as patients with pT1mi/a-bN0-1 HR+HER2- or pT1mi/a-bN0 HR-HER2-/HR+HER2+ can be exempted from chemotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.